Overview: HHV6 Antibody Panel TestIntroduction: The HHV6 Antibody Panel Test detects IgG and IgM antibodies to human herpesvirus 6 (HHV-6) to diagnose infection, causing fever or rash. Aligned with 2023 IDSA guidelines, it uses an immunoassay for high sensitivity, aiding in infectious disease screening. This test is critical for guiding diagnosis, management, and improving outcomes in serology for patients with suspected HHV-6 infection, often linked to roseola in children or reactivation in immunocompromised individuals.
Other Names: HHV-6 Ab Assay, Human Herpesvirus 6 Serology Test.
FDA Status: Laboratory-developed test (LDT), meeting serology standards for diagnostic accuracy.
Historical Milestone: HHV-6 antibody testing began in the 1980s after virus identification. Immunoassays improved in the 2000s, enhancing infection detection.
Purpose: Diagnoses HHV-6 infection, guides management, and monitors IgG and IgM antibodies in patients with fever or rash.
Test Parameters: 1. HHV-6 IgG & IgM
Pretest Condition: No fasting required. Collect serum, CSF, or saliva at any time. Report symptoms like fever, rash, or neurological symptoms, and list medications or immunosuppression status.
Specimen: 2-5 mL serum (SST), 1-2 mL CSF (sterile container), or 1-2 mL saliva (sterile container). Centrifuge serum or CSF within 1 hour. Transport in a biohazard bag within 8 hours.
Sample Stability at Room Temperature: 8 hours
Sample Stability at Refrigeration: 7 days
Sample Stability at Frozen: 6 months
Medical History: Document fever, rash, neurological symptoms, or history of HHV-6 exposure. Include current medications, especially antivirals, and immunosuppression status.
Consent: Written consent required, detailing the tests purpose, diagnostic implications, and potential need for antiviral therapy or monitoring.
Procedural Considerations: Uses an immunoassay to detect HHV-6 IgG and IgM antibodies. Results are available in 3-5 days, enabling clinical decisions. Performed in laboratories, often for immunocompromised patients.
Factors Affecting Result Accuracy: Improper sample handling or cross-reactivity with other herpesviruses can affect results. Early infection may yield false negatives.
Clinical Significance: Positive IgM indicates acute HHV-6 infection, while IgG suggests past infection or reactivation. Results guide antiviral therapy or monitoring in immunocompromised patients.
Specialist Consultation: Consult an infectious disease specialist or pediatrician for result interpretation and management planning.
Additional Supporting Tests: HHV-6 PCR, CBC, or liver function tests to confirm active infection and assess clinical impact.
Test Limitations: Cross-reactivity with other herpesviruses may occur. Clinical correlation and confirmatory testing are needed.
References: IDSA Herpesvirus Guidelines, 2023; Journal of Infectious Diseases, Yamanishi K, 2022.
